All groups of strep cause the same diseases
----- For those who want details -----
Too many details, jargon of little relevance.
Basically they all cause similar diseases, similar antibiotics
- some give fever and others do not
- some give red blood cell problems
- some give white blood cell problems
Types of strep, invasive ratio, treatment:
- Group A strep (GAS), 40%, difficult, more than penicillin needed
- Group B strep (GBS), 32%, azithromycin
- Group C strep (GBS), 23%, penicillin
- Group G strep (GBS), 6%,
- --------
- = 100%
Risk factors (74% of the time) people first have
- heart disease
- lung disease
- diabetes
- cancer
- No group predominates underlying conditions
26% of the time there are no underlying health conditions especially in young children, teenagers and otherwise healthy individuals.
Group A
- β-hemolytic - Beta Hemolytic Streptococcus - Group A Strep
- Attacks red blood cells,
- lyric, lysis; to cut or break apart
- low levels of red blood cells
- chronic
- cancer
- known for causing
- sore throat - pharyngitis and its sequel
- fever - acute rheumatic fever
- kidney infections - post streptococcal glomerulonephritis
- skin infections,
- invasive disease
- joint infections, arthritis
Of all the streptococci, GAS are the most pathogenic for humans.
Group B
Group C and G
- less common to have a fever
- slower growing
- sinusitis
- low blood pressure
----- archived reference -----
Clin Microbiol Infect
2005 Jul;11 (7): 569-76.
Invasive group A, B, C and G streptococcal infections in Denmark 1999-2002: epidemiological and clinical aspects
K Ekelund 1 , P Skinhøj, J Madsen, H B Konradsen
PMID:15966976
Free article
Abstract
Group A streptococci (GAS) have been described frequently as an emerging cause of severe invasive infections in population-based surveillance studies, whereas the descriptions of group B, C and G streptococci (GBS, GCS and GGS) have been less frequent. Enhanced surveillance for invasive GAS, GBS, GCS and GGS was performed in Denmark in 1999-2002. A detailed questionnaire was completed for 1237 (98%) of 1260 invasive infections. GAS infections dominated (40%), followed by GGS (32%), GBS (23%) and GCS (6%). Most (74%) patients had predisposing factors, and there were no significant differences between the four serogroups when comparing the prevalence of cancer, diabetes mellitus, chronic heart or lung diseases, immunodeficiency or alcohol abuse. The overall case fatality rate at day 30 was 21%, increasing significantly to 59% for patients with streptococcal toxic shock syndrome (STSS). STSS was significantly more frequent in GAS patients (10%) than in GCS (4%), GBS (2%) and GGS (2%) patients. Regression analyses showed that, despite a younger median age among GAS patients, the probability of developing septic shock and mortality was significantly higher among GAS patients than among GBS and GGS patients. These analyses showed no significant differences between GAS and GCS infections. Invasive infections caused by GAS, GBS, GCS and GGS are still a major challenge for clinicians. Continued epidemiological and microbiological surveillance is important to assess the development of these infections and to improve preventative strategies.